Thrombosis News and Research

Latest Thrombosis News and Research

Maternal obesity may contribute to cognitive impairment in extremely premature babies

Maternal obesity may contribute to cognitive impairment in extremely premature babies, according to a new study by researchers at Wake Forest Baptist Medical Center.

9 Mar 2012

MEDVAMC initiates Aeterna Zentaris' AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the Michael E. DeBakey Veterans Affairs Medical Center, in Houston, Texas, has initiated a Phase 2A trial assessing the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130 (macimorelin), in patients with cancer cachexia.

9 Mar 2012

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

The agenda for the Optimizing PCI Outcomes: A Vision for 2012 symposium is now available at: http://www.pcioutcomes.com/conference/agenda.html. This evening symposium will feature the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease, including the latest clinical data on current and second-generation drug-eluting stent device-based therapies.

8 Mar 2012

AcelRx initiates ARX-01 Phase 3 study for treatment of post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported dosing of the first patient in a Phase 3 study for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system.

6 Mar 2012

BioInvent completes enrollment in BI-204 phase IIa study for atherosclerosis

BioInvent International AB and its collaborator Genentech, a member of the Roche Group, announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease.

2 Mar 2012

SuperFAK protein decreases damage from heart attack by 50%

Researchers from the University of North Carolina at Chapel Hill reduced damage from a heart attack by 50 percent by enhancing a protective protein found in mice and humans.

2 Mar 2012

SIR to showcase latest minimally invasive treatments at 37th annual meeting

Health, science and medical reporters are invited to register now for the Society of Interventional Radiology's 37th Annual Scientific Meeting March 24 at Moscone Center (North), San Francisco, Calif. The meeting's theme, "IR Evidence," was chosen to focus on the results of care-changing investigations that showcase research into minimally invasive treatments that provide treatment options, advance patient care and improve quality of life.

1 Mar 2012

Scientists develop safer and more accurate way to administer warfarin

A team of global scientists, led by researchers at Intermountain Medical Center in Salt Lake City, has developed a safer and more accurate way to administer warfarin, one of the most commonly prescribed but also potentially dangerous medications in the United States.

1 Mar 2012

LAU-0901 drug protects brain in an experimental stroke model

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke.

29 Feb 2012

Scientists produce mathematical model of calcium activity within atrial heart cell

What we perceive as the beating of our heart is actually the co-ordinated action of more than a billion muscle cells. Most of the time, only the muscle cells from the larger heart chambers contract and relax. But when the heart needs to work harder it relies on back-up from the atrial muscle cells deep within the smaller chambers (atria) of the heart.

18 Feb 2012

FDA approves Medtronic's Resolute Integrity DES to treat CAD

Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease.

From Medtronic 17 Feb 2012

Direct link between short telomere length, heart attack and early death

Every cell in the body has chromosomes with so-called telomeres, which are shortened over time and also through lifestyle choices such as smoking and obesity. Researchers have long speculated that the shortening of telomeres increases the risk of heart attack and early death. Now a large-scale population study in Denmark involving nearly 20,000 people shows that there is in fact a direct link, and has also given physicians a future way to test the actual cellular health of a person.

16 Feb 2012

Curcumin prolongs life and enhances activity of fruit flies with AD

Curcumin, a substance extracted from turmeric, prolongs life and enhances activity of fruit flies with a nervous disorder similar to Alzheimers. The study conducted at Link-ping University, indicates that it is the initial stages of fibril formation and fragments of the amyloid fibrils that are most toxic to neurons.

15 Feb 2012

New clinical guidelines for diagnosis and treatment of DVT

A researcher at Intermountain Medical Center in Salt Lake City is part of a select panel of international experts to help develop new evidence-based clinical guidelines used by physicians worldwide for the diagnosis and treatment of blood-clotting disorders, one of the most common cardiovascular diseases in the United States.

15 Feb 2012

Anticoagulation drugs can prevent PE, DVT after total joint replacement

Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs.

7 Feb 2012

Top-line results from Merck's vorapaxar clinical study on thrombosis

Merck, known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar.

7 Feb 2012

New ACCP guidelines address DVT/PE risk factors for long-distance travel

New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.

7 Feb 2012

Positive clinical results from randomized trial of InspireMD's MGuard in STEMI patients

InspireMD, Inc., a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced positive clinical results from an investigator-sponsored controlled randomized trial conducted in Chile.

6 Feb 2012

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment

3 Feb 2012

Postmenopausal women at higher risk of stroke than they think

A new study by researchers at NYU Langone Medical Center and colleagues found that traditional risk factors for stroke - such as high cholesterol - are not as accurate at predicting risk in postmenopausal women as previously thought. Instead, researchers say doctors should refocus their attention on triglyceride levels to determine which women are at highest risk of suffering a devastating and potentially fatal cardiovascular event.

3 Feb 2012